Literature DB >> 15746247

Sequence requirements for oligodeoxyribonucleotide inhibitory activity.

Robert F Ashman1, J Adam Goeken, Jennifer Drahos, Petar Lenert.   

Abstract

Inhibitory oligonucleotides (IN-ODN) differing from stimulatory CpG ODN (ST-ODN) by as few as two bases can block ST-ODN-induced proliferation, apoptosis protection and IL-6 secretion in B lymphocytes and the production of IL-12p40 by non-B cells. The main objective of this study was to determine the ODN sequence requirements for inhibition in mice. Starting with a strongly inhibitory 15-mer prototype phosphorothioate sequence, we tested the 60 sequences that differed from the prototype by one base, revealing the three areas that are critical for activity. Between these areas were the spacer sequences where base composition mattered little, but the number of bases was important. Truncation of three bases at the 3' end of the 15-mer and one at the 5' end was tolerated with minimal loss of activity. This approach yielded an 'optimal' sequence of 5' CC x notC notC xxGGGx or CC x notC notC xGGGxx 3', where x is any base. The sequence requirements for optimal inhibition of B cell responses to Type B (K) ODN and mixed splenocyte IL-12p40 responses to Type A (D) ODN were strikingly similar. Inhibition of ST-ODN by IN-ODN was competitive. A hypothetical model of the ODN-binding site is proposed. Synthetic IN-ODN with the sequence characteristics defined here should provide antidotes for excessive innate reactions to DNA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15746247     DOI: 10.1093/intimm/dxh222

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  15 in total

Review 1.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

2.  Engagement of the B cell receptor for antigen differentially affects B cell responses to Toll-like receptor-7 agonists and antagonists in BXSB mice.

Authors:  T Layer; A Steele; J A Goeken; S Fleenor; P Lenert
Journal:  Clin Exp Immunol       Date:  2011-01-14       Impact factor: 4.330

3.  Competition by inhibitory oligonucleotides prevents binding of CpG to C-terminal TLR9.

Authors:  Ana M Avalos; Hidde L Ploegh
Journal:  Eur J Immunol       Date:  2011-09-06       Impact factor: 5.532

4.  Aggregation and secondary loop structure of oligonucleotides do not determine their ability to inhibit TLR9.

Authors:  Robert F Ashman; J Adam Goeken; Petar S Lenert
Journal:  Int Immunopharmacol       Date:  2011-03-02       Impact factor: 4.932

Review 5.  Modulating toll-like receptor 7 and 9 responses as therapy for allergy and autoimmunity.

Authors:  Damir Matesic; Aleksander Lenert; Petar Lenert
Journal:  Curr Allergy Asthma Rep       Date:  2012-02       Impact factor: 4.806

6.  Structure-dependent modulation of alpha interferon production by porcine circovirus 2 oligodeoxyribonucleotide and CpG DNAs in porcine peripheral blood mononuclear cells.

Authors:  Frida Hasslung Wikström; Brian M Meehan; Mikael Berg; Sirje Timmusk; Josefine Elving; Lisbeth Fuxler; Mattias Magnusson; Gordon M Allan; Francis McNeilly; Caroline Fossum
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

Review 7.  Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.

Authors:  Petar S Lenert
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

Review 8.  Structural requirements and applications of inhibitory oligodeoxyribonucleotides.

Authors:  Robert F Ashman; Petar Lenert
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

9.  Extended sequence preferences for oligodeoxyribonucleotide activity.

Authors:  Petar Lenert; Adam J Goeken; Robert F Ashman
Journal:  Immunology       Date:  2006-04       Impact factor: 7.397

10.  DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo.

Authors:  Petar Lenert; Kei Yasuda; Liliana Busconi; Patrice Nelson; Courtney Fleenor; Radhika S Ratnabalasuriar; Peter L Nagy; Robert F Ashman; Ian R Rifkin; Ann Marshak-Rothstein
Journal:  Arthritis Res Ther       Date:  2009-05-28       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.